Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen K Chia

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Neoadjuvant and Adjuvant Therapy for HER2 Positive DiseaseStephen K Chia
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Treatment algorithms for hormone receptor-positive advanced breast cancer: applying the results from recent clinical trials into daily practice—insights, limitations, and moving forwardSheridan Wilson, Stephen K Chia
Cancer Journal (Sudbury, Mass.)|February 19, 2010
What is the difference between triple-negative and basal breast cancers?Melanie D Seal, Stephen K Chia
Current Oncology (Toronto, Ont.)|August 25, 2023
Current Challenges and Disparities in the Delivery of Equitable Breast Cancer Care in CanadaEmily B Jackson, Christine E Simmons, Stephen K Chia
Oncoimmunology|November 1, 2018
TIM-3 expression in breast cancerSamantha Burugu, Dongxia Gao, Samuel Leung, et al.
BMC Cancer|July 13, 2018
Understanding adjuvant endocrine therapy persistence in breast Cancer survivorsLeah K Lambert, Lynda G Balneaves, A Fuchsia Howard, et al.
The Oncologist|January 24, 2012
Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumorRobyn Macfarlane, Melanie Seal, Caroline Speers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapiesStephen K Chia, Caroline H Speers, Cicely J Bryce, et al.
The Oncologist|November 20, 2016
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast CancerKathleen I Pritchard, Stephen K Chia, Christine Simmons, et al.
Journal of Bone Oncology|November 19, 2015
Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-studyChristina L Addison, Gregory R Pond, Brandy Cochrane, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Neoadjuvant and Adjuvant Therapy for HER2 Positive DiseaseStephen K Chia
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Treatment algorithms for hormone receptor-positive advanced breast cancer: applying the results from recent clinical trials into daily practice—insights, limitations, and moving forwardSheridan Wilson, Stephen K Chia
Cancer Journal (Sudbury, Mass.)|February 19, 2010
What is the difference between triple-negative and basal breast cancers?Melanie D Seal, Stephen K Chia
Current Oncology (Toronto, Ont.)|August 25, 2023
Current Challenges and Disparities in the Delivery of Equitable Breast Cancer Care in CanadaEmily B Jackson, Christine E Simmons, Stephen K Chia
Oncoimmunology|November 1, 2018
TIM-3 expression in breast cancerSamantha Burugu, Dongxia Gao, Samuel Leung, et al.
BMC Cancer|July 13, 2018
Understanding adjuvant endocrine therapy persistence in breast Cancer survivorsLeah K Lambert, Lynda G Balneaves, A Fuchsia Howard, et al.
The Oncologist|January 24, 2012
Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumorRobyn Macfarlane, Melanie Seal, Caroline Speers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapiesStephen K Chia, Caroline H Speers, Cicely J Bryce, et al.
The Oncologist|November 20, 2016
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast CancerKathleen I Pritchard, Stephen K Chia, Christine Simmons, et al.
Journal of Bone Oncology|November 19, 2015
Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-studyChristina L Addison, Gregory R Pond, Brandy Cochrane, et al.
Pageof 4